Overview
Analysis Key terms
About H.LUNDBECK 25/29 MTN
Sector
Health Technology
Industry
Pharmaceuticals: Major
Home page
ISIN
XS3081808837
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. It operates through the following geographical segments: Europe, United States, and International Markets. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.
Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.